Skip to main content


Second Bankruptcy Bid Linked to Talc by J&J Turned Down

 Johnson & Johnson's (J&J) endeavor to reach an $8.9 billion settlement and seek bankruptcy protection for talc-related lawsuits has been denied for the second time, as of July 30, 2023. The decision came from Judge Michael Kaplan of the U.S. Bankruptcy Court in New Jersey, who ruled that the company's financial situation was not critically dire, as reported by the New York Times . The rejection prompts J&J to challenge the verdict robustly, vowing to counter the lawsuits that they deem lacking in scientific basis, according to Reuters . In response to the wave of legal actions alleging that J&J's talc-infused baby powder contained cancer-causing asbestos, the corporation established a subsidiary called LTL Management in 2021. The subsidiary filed for Chapter 11 bankruptcy protection, a move contested by J&J, leading to a series of legal maneuvers. The initial appeal was turned down in March 2023, with noting that the parent company had
Recent posts

Exploring Germline Genetic Variants Among Individuals Affected by Mesothelioma

 Recent Findings in JAMA Network Open Suggest Potential Benefits of Comprehensive Germline Genetic Testing for Mesothelioma Patients. While asbestos exposure remains a primary risk factor for mesothelioma, a segment of patients also carry harmful genetic variations that amplify susceptibility to solid tumors. Researchers, led by a team from the University of Chicago, investigated 161 mesothelioma patients who underwent both tumor-specific and germline next-generation sequencing. Results indicated that 16% of patients bore pathogenic or potentially pathogenic genetic variations, predominantly within a gene associated with hereditary cancer syndromes. These genetic alterations were detected at a similar frequency to other tumor types like metastatic prostate cancer, epithelial ovarian cancer, and exocrine pancreatic cancer, all of which recommend universal germline genetic testing. Given the comparable prevalence of P/LP germline variants in mesothelioma patients to other cancers where

RS Oncology Unveils Innovative Drug in Initial Clinical Trials for Mesothelioma and Lung Cancer Treatment

  Newly Established U.S. Biotechnology Firm Specializing in Rare Conditions Introduces Three Case Studies in France LILLE, France, August 03, 2023--(BUSINESS WIRE)--With a focus on offering groundbreaking scientific advancements to those patients who are most likely to gain from emerging treatments, RS Oncology introduces PRX3. This unique drug target has promising potential for the therapy of mesothelioma, a type of cancer linked to asbestos. Positioned in the mitochondria, or the cellular powerhouses, PRX3 serves as a vital protection against oxidative stress, selectively targeting cancer cells and sparing healthy ones. You can access the entire release, which includes multimedia elements, at the following link: A first-of-its-kind Phase 1 clinical trial named MITOPE is currently assessing PRX3 inhibitor RSO-021 (find more details at, identifier NCT05278975, under the sponsorship of RS Oncology, LLC [RSO], b

UPDATE: Johnson & Johnson's Proposed Solution to Bankruptcy Dismissed Once More

Johnson & Johnson's continuous attempts to elude going to trial over talc and asbestos accusations were thwarted again, leaving the company in a precarious state as they confront over tens of thousands of legal claims. These claims stem from Johnson & Johnson's talc Baby Powder and allegations concerning asbestos exposure. The $8.9 billion bankruptcy settlement proposal by Johnson & Johnson was turned down, and the case was dismissed by Judge Michael Kaplan of the U.S. Bankruptcy Court for the District of New Jersey. In his court filing, the judge stated that Johnson & Johnson is not under any "immediate or imminent financial distress." The substantial amount of $8.9 billion that Johnson & Johnson suggested was intended to resolve all ongoing and future lawsuits tied to their now-ceased talc-based Baby Powder. As reported by the New York Times, Johnson & Johnson is facing an estimated 60,000 cases. These cases involve consumers who used the tal

Mesothelioma: A Current Overview

Introduction Mesothelioma is a rare and aggressive form of cancer that primarily affects the lining of the lungs, abdomen, and heart. Most commonly associated with asbestos exposure, the disease continues to challenge researchers and medical professionals. Recent developments in treatment, legal issues surrounding asbestos, and ongoing research offer a glimpse into the current state of mesothelioma. Recent Medical Advancements Immunotherapy: There has been growing interest in the use of immunotherapy for treating mesothelioma. Some trials have shown promising results in enhancing the body's immune response to fight the cancer cells. Gene Therapy: Researchers are exploring the possibility of altering or replacing defective genes associated with mesothelioma to stop or slow down the progression of the disease. Surgery and Chemotherapy: Advances in surgical techniques and chemotherapy delivery methods offer hope for better survival rates and improved quality of life for patients. Leg

Mesothelioma: Understanding a Rare but Deadly Cancer

Introduction Mesothelioma is a rare and aggressive form of cancer that affects the thin layer of tissue, known as the mesothelium, which covers the internal organs of the body. This disease is primarily associated with exposure to asbestos, a naturally occurring mineral that was widely used in construction, shipbuilding, and manufacturing industries before its health risks were well-known. This article aims to provide an overview of mesothelioma, including its causes, symptoms, diagnosis, and treatment options. Causes of Mesothelioma The primary cause of mesothelioma is asbestos exposure. Asbestos is a fibrous material that was extensively used in the past for its heat-resistant properties and insulation capabilities. When asbestos fibers are inhaled or ingested, they can become lodged in the lining of the lungs, abdomen, or heart, leading to chronic inflammation and eventually causing cancerous changes in the mesothelial cells. However, it is important to note that not everyone expose